Novo Nordisk (CPSE:NOVO B) Enlists Shantha Biologics For Cartridge Manufacturing In India

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Novo Nordisk has entered into an outsourcing agreement with Shantha Biologics for cartridge fill-finish manufacturing services in India. The partnership expands Novo Nordisk's production footprint into a key pharmaceutical manufacturing hub. The deal is intended to support the company's global supply chain and its ability to meet demand for cartridge-based products.

Novo Nordisk, traded as CPSE:NOVO B, is making this move while its share price stands at DKK314.6. The stock is up 2.2% over the past week and 7.4% over the past month, although it is down 4.7% year to date and has declined 24.9% over the past year. Over five years, the stock is up 31.2%, with a weaker patch over three years where it is down 37.0%.

For investors watching Novo Nordisk, this new agreement with Shantha Biologics highlights how the company is using external partners to support cartridge production in a key market. The development may matter for how reliably the company can supply products globally and how it manages its manufacturing footprint over time.

Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.CPSE:NOVO B Earnings & Revenue Growth as at Jul 2026

3 things going right for Novo Nordisk that this headline doesn't cover.

This outsourcing deal gives Novo Nordisk another lever to support its GLP-1 and broader injectable portfolio by adding cartridge fill-finish capacity in India. Rather than building all capacity in-house, the company is using Shantha Biologics as a specialist partner to handle a technically sensitive step in the manufacturing process, which can be important for pens and cartridges used in diabetes and obesity treatments. For you as an investor, the key angle is operational, not headline size: this agreement speaks to how Novo Nordisk is trying to make its supply chain more resilient and flexible in a context where Eli Lilly and other large pharmaceutical companies are also scaling production for metabolic drugs.

How This Fits Into The Novo Nordisk Narrative

The agreement supports the existing narrative that manufacturing investments and capacity expansion are important for Novo Nordisk, by adding third party cartridge production alongside its own sites to help address supply constraints. Relying on an external partner could challenge the narrative that tighter control over production automatically improves earnings quality, because it adds another layer of coordination, quality oversight, and potential cost variability. The role of India as a cartridge manufacturing hub, and how contract partners fit into Novo Nordisk's long term supply map, is not fully reflected in the narrative focus on internal plants in Europe and North America.

Story Continues

Knowing what a company is worth starts with understanding its story.Check out one of the top narratives in the Simply Wall St Community for Novo Nordisk to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

Using an outsourced cartridge partner introduces execution risk if quality, regulatory compliance, or delivery timelines at Shantha Biologics fall short, which could disrupt Novo Nordisk's product supply. Coordinating complex supply chains across multiple regions may add cost pressure and operational complexity compared with a more centralized in house setup, especially when competitors such as Eli Lilly or Pfizer pursue different manufacturing strategies. Access to additional cartridge fill-finish capacity in India may improve Novo Nordisk's ability to support demand for GLP-1 and other injectable therapies without committing the same level of upfront capital to new internal facilities. A broader production footprint and a trusted third party partner can help Novo Nordisk manage regional supply needs and potentially reduce single site disruption risk relative to a more concentrated manufacturing base.

What To Watch Going Forward

From here, investors can watch for updates on how quickly Shantha Biologics ramps into commercial production for Novo Nordisk, any comments on supply reliability from management, and whether further outsourcing deals are signed in other regions. It is also useful to track how this sits alongside Novo Nordisk's own capacity projects and how competitors structure their manufacturing for GLP-1 and other biologics, as that shapes long term cost and supply dynamics for the sector.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Novo Nordisk, head to the community page for Novo Nordisk to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NOVO-B.CO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments